Start here if you're new
what it is
Biogen sells neurology drugs, lives off aging blockbusters, and needs new medicines to outrun old-product decay.
how it gets paid
Last year Biogen made $9.9B in revenue. Product revenue was the main engine at $7.13B, or 72% of sales.
why it's growing
Revenue grew 2.2% last year. The 46.32% EPS surprise mattered most because it showed Biogen can still defend profits even when top-line growth looks tired.
what just happened
Biogen beat on profit, posting $1.99 in EPS versus a $1.36 estimate, even as investors worried about 2026 revenue pressure.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
45/100 earnings predictability — expect surprises
12.9x trailing p/e — the market's not buying it — or you found a deal
8.5% return on capital — nothing to write home about
xvary composite: 58/100 — below average
What they do
Biogen sells neurology drugs, lives off aging blockbusters, and needs new medicines to outrun old-product decay.
Biogen wins where neurologists already trust the playbook. It spent 17.5% of sales on R&D in 2025, which means research and development → money spent finding new drugs → you are paying for future shots on goal. The sticky part is doctor behavior and rare-disease expertise, not scale. You do not switch serious brain-disease treatments casually, and that gives Biogen time to defend a 25.9% net profit margin.
How they make money
$9.9B
annual revenue · their business grew +2.2% last year
Product revenue
$7.13B
Unconsolidated joint business
$2.08B
Royalties
$0.69B
The products that matter
legacy multiple sclerosis franchise
MS portfolio
over 40% of sales
This is still the center of gravity. The page data says the MS category makes up over 40% of sales, and it is the part facing generic competition and steady erosion.
aging cash engine
newer growth drugs
Leqembi, Skyclarys, Qalsody, Zurzuvae
$1B last year
These four products generated a combined $1B in sales last year. They are smaller than the legacy franchise, but they are the part of the portfolio that has to matter more from here.
the handoff
commercial reset story
cost cuts + pipeline
$15.25–$16.25 guide
Management guided to $15.25–$16.25 in 2026 EPS while targeting roughly $9B in revenue. In plain English: Biogen is trying to protect earnings while the product mix changes underneath it.
profit defense
Key numbers
12.9x
trailing p/e
P/E ratio → how many dollars you pay for $1 of profit → you are paying a market-average multiple for a business with shrinking legacy products.
45.0%
operating margin
Operating margin → profit after running the business → Biogen still throws off a lot of cash from each sales dollar even with weak growth.
$9.9B
annual revenue
Revenue → total money coming in → Biogen added just 2.2% vs. prior year, which tells you the business is stable, not fast-moving.
8.5%
return on capital
Return on capital → profit generated from the money tied up in the business → this is fine, not elite, for a drug company with big pipeline needs.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 45 / 100
- long-term debt $6.3B (18% of capital)
- net profit margin 25.9% — keeps 26 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in BIIB 3 years ago → it's now worth $6,770.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
Biogen beat on profit, posting $1.99 in EPS versus a $1.36 estimate, even as investors worried about 2026 revenue pressure.
Fourth-quarter sales came in around $2.28B, above the $2.2B consensus cited in the company write-up. The quiet part: full-year 2025 sales rose only 2%, while adjusted EPS fell 7% to $15.28.
$2.28B
revenue
$1.99
eps
n/a
n/a
the number that mattered
The 46.32% EPS surprise mattered most because it showed Biogen can still defend profits even when top-line growth looks tired.
-
biib rose another 20% in value since our late november review.
-
fourth-quarter sales and adjusted share earnings beat consensus estimates of $2.2 billion and $1.63, respectively, though vs. prior year comparisons were down on an apples-to-apples basis. (note that beginning with 2025, our presentation is based on adjusted earnings.) sales growth was sturdy across the newer drugs, including leqembi (in collaboration with eisai co. for alzheimer’s disease), skyclarys (rare neurodegenerative disease), qalsody (als), and zurzuvae (postpartum depression).
-
but, with the exception of vumerity, the ms unit saw declines.
-
for all of 2025, sales rose a modest 2%, while adjusted share profit fell 7%.the biotech company is counting on a number of growth drugs to help offset weakness in the ms business.
-
biogen has been looking to compensate for its struggling ms category (which makes up over 40% of sales and faces stiff generic competition and sales erosion) via strategic portfolio shifts toward areas like alzheimer’s and rare diseases.non-ms growth drugs leqembi, skyclarys, qalsody, and zurzuvae generated a combined $1 billion in sales last year, and biogen expects the momentum to continue in 2026.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is multiple sclerosis franchise erosion. The page data says MS still makes up over 40% of sales, so every decline there hits the income statement before the newer drugs are large enough to fully offset it.
med
MS decline outruns the replacement cycle
Biogen is still anchored by older multiple sclerosis therapies. Generic competition and sales erosion are already in the story, and the franchise still represents over 40% of sales.
If that erosion accelerates, the $9B 2026 revenue setup gets harder to defend.
med
newer drugs stay too small for too long
Leqembi, Skyclarys, Qalsody, and Zurzuvae generated a combined $1B last year. Useful, but still not large next to a $9.9B company.
If the newer portfolio does not scale, you are left with a lower-multiple runoff story rather than a relaunch.
med
regulatory and legal noise becomes more than noise
Biogen faces an antitrust probe in Italy tied to its biosimilars business and a shareholder lawsuit alleging misleading statements. The numbers here are thin, which is exactly why the risk is hard to price cleanly.
These may not break the thesis on their own, but they add friction to a company already managing a portfolio transition.
Over 40% sales exposure to the legacy MS base means the new-drug portfolio has to carry more than optimism. It has to carry the math.
source: institutional data · regulatory filings · risk analysis
Pay attention to
revenue floor
the $9B 2026 revenue setup
Biogen just printed $9.9B in annual revenue. If the business settles near $9B while earnings hold, the low multiple starts to look more interesting.
portfolio shift
whether the newer drugs scale fast enough
The newer group produced $1B last year. That is the handoff you need to see get bigger while the legacy franchise fades.
core risk
MS sales erosion
The MS category still makes up over 40% of sales. That means each decline there matters more than almost any headline around the pipeline.
calendar
may 2026 FDA review
A subcutaneous Alzheimer’s formulation is up for FDA review in May 2026. That is one of the cleaner near-term catalysts on this page.
Analyst rankings
short-term outlook
average
momentum score 3. In human-speak, analysts are not calling for a near-term collapse or a breakout.
risk profile
average
stability score 3 means BIIB lands in the middle of the pack on risk. Not a bunker stock. Not chaos either.
chart momentum
top 20%
technical score 2 means above-average price performance expectations in the year ahead. The chart looks stronger than the narrative feels.
earnings predictability
45 / 100
The earnings line is still noisy. That fits a company changing product mix, cost structure, and earnings presentation at the same time.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 428 buyers vs. 329 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$111
$242
$197
current price
$177
target midpoint · 10% from current · 3-5yr high: $300 (+55% · 11% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive